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Introduction: Diagnoses of anxiety and/or depres-
sion are common in subjects at Ultra-High Risk for 
Psychosis (UHR) and associated with extensive functional 
impairment. Less is known about the impact of affective 
comorbidities on the prospective course of attenuated 
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modelling identified APS trajectories in 331 UHR subjects 
assessed at baseline, 6, 12, and 24 months follow-up. The 
prognostic value of past, baseline, and one-year DSM-IV 
depressive or anxiety disorders on trajectories was investi-
gated using logistic regression, controlling for confounders. 
Cox proportional hazard analyses investigated associ-
ations with transition risk. Results: 46.8% of participants 
fulfilled the criteria for a past depressive disorder, 33.2% 
at baseline, and 15.1% at one-year follow-up. Any past, 
baseline, or one-year anxiety disorder was diagnosed in 
42.9%, 37.2%, and 27.0%, respectively. Participants were 
classified into one of three latent APS trajectory groups: 
(1) persistently low, (2) increasing, and (3) decreasing. 
Past depression was associated with a higher risk of be-
longing to the increasing trajectory group, compared to the 
persistently low (OR  =  3.149, [95%CI: 1.298–7.642]) or 
decreasing group (OR = 3.137, [1.165–8.450]). In contrast, 
past (OR  =  .443, [.179–1.094]) or current (OR  =  .414, 
[.156–1.094]) anxiety disorders showed a trend-level associ-
ation with a lower risk of belonging to the increasing group 
compared to the persistently low group. Past depression was 
significantly associated with a higher risk of transitioning 
to psychosis (HR = 2.123, [1.178–3.828]). Conclusion: A 
past depressive episode might be a particularly relevant risk 
factor for an unfavorable course of APS in UHR individ-
uals. Early affective disturbances may be used to advance 
detection, prognostic, and clinical strategies.
Key words:  ultra-high risk/comorbid/anxiety/depression
/psychosis/schizophrenia/prediction
Introduction
Of all individuals meeting the criteria for the ultra-high 
risk state for psychosis (UHR), meta-analysis estimate 
that 23% (95%CI: 18%–29%) will develop a psychotic dis-
order within two-years after presentation to clinical serv-
ices.1,2 The risk of psychosis is the highest in the subgroup 
with brief  intermittent psychotic symptoms (BLIPS), 
lowest in the group with genetic risk in combination with 
a significant decline in functioning (Genetic Risk and 
Deterioration syndrome, GRD), and intermediate in the 
subgroup with subthreshold attenuated psychotic symp-
toms (APS).3 UHR individuals often display considerable 
impairment in functioning and a reduction in quality of 
life.4 However, they represent a highly heterogeneous 
group in terms of clinical and functional outcome. With 
regard to comorbid (supplementary eIntroduction 1.1 
elaborates on the term “comorbid”) psychiatric diag-
nosis, apart from substance misuse5 and personality dis-
orders,6 mood (41%), and/or anxiety disorders (15%) are 
reported as the most frequent co-occurring conditions.7–10 
These comorbid affective diagnoses tend to persist and 
are associated with increased experienced distress and a 
lower level of global and psychosocial functioning over 
time.7,11–13 Affective symptoms have furthermore been 
reported as the primary subjective reasons for UHR in-
dividuals to seek help at specialized early intervention 
services.13
Over the last two decades, the main focus of UHR-
research has been the identification of predictors for 
transition to psychosis.14 Regarding the prognostic va-
lidity of comorbid affective disorders, meta-analyses 
found no effect on the risk of transition.7,8 There has been 
limited research investigating the association between af-
fective comorbidity and long-term course of psychotic 
symptoms other than transition risk15 (supplementary 
eIntroduction 1.2 summarizes associations with other 
outcome variables).
One previous study found no association between the 
presence of a current comorbid depressive disorder and 
the likelihood of remission from UHR state.5 However, 
the authors reported a significant association between 
the presence of a current anxiety disorder and persist-
ence of symptoms. In contrast, another previous study 
reported that both depressive and anxiety disorder pre-
dicted persistence of paranoid symptoms.16 Only one 
study reported a combination of current and/or lifetime 
comorbid depression and found that this was associated 
with a decreased likelihood of remission from the UHR 
state.17 Another study assessed comorbidity repeatedly 
and found no association between persistence or recur-
rence of affective disorders and persistence of APS over 
a six-year period.12 Overall, it seems that the evidence is 
inconsistent and mainly limited to associations between 
co-occurring affective disorders assessed at baseline and 
remission status at a specific time point. However, depres-
sive symptoms often seem to appear prior to APS onset 
and may affect the clinical course.18,19 In accordance, a 
general population study found a decrease in positive and 
an increase in negative affect to be associated with per-
sistence of psychotic experiences over time as compared 
to transient psychotic experiences.20 To the best of our 
knowledge, no study has investigated the relative impact 
of past, baseline, or prospectively assessed comorbid 
depressive and anxiety disorder on UHR trajectories. 
Hence, the added value of repeatedly assessed comorbid 
affective disorders on clinical trajectories of APS in UHR 
individuals remains unclear.
The current study aimed to address this question by 
examining trajectories of APS severity over a two-year 
period in UHR individuals with latent class mixed mod-
elling (LCMM). We subsequently investigated the prog-
nostic value of past, baseline, or one-year comorbidity 
of anxiety or depression on these trajectories. As a sec-
ondary aim, we sought to investigate whether past, base-
line, or one-year affective comorbidity was associated 
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Method
Study Design and Participants
The data analyzed in this study were collected within the 
multicenter European Gene-Environment Interactions 
(EU-GEI) study, from May, 2010 to April, 2015. The 
aim of the EU-GEI study is to identify the interactive 
genetic, clinical, and environmental determinants, in-
volved in the development, severity, and outcome of 
psychotic disorders.21 The design and inclusion criteria 
of  the prodrome/high-risk study of  EU-GEI have pre-
viously been described in detail.22 In short, the overall 
design of  the study was naturalistic and prospective, 
consisting of  a baseline and two or three follow-up time 
points depending on the outcome measure. Subjects 
were recruited from 11 mental healthcare institutions 
in: London, Amsterdam, The Hague, Vienna, Basel, 
Cologne, Melbourne, Kortenberg, Paris, Barcelona, 
and Sao Paulo. The study protocol was approved by 
the Medical Ethics Committees of  all participating 
sites. EU-GEI was conducted in accordance with the 
Declaration of  Helsinki.
Subjects presenting at participating healthcare institu-
tions aged 15–35 were eligible for the study if  they met 
criteria of the Comprehensive Assessment of At-Risk 
Mental States (CAARMS)23 for the UHR state classi-
fied into one or more of the following three groups: (1) 
GRD: schizotypal personality disorder or having a first 
degree relative with a psychotic disorder and experien-
cing a significant decline in or chronic low psychosocial 
functioning, (2) APS: having positive psychotic symp-
toms that do not reach the threshold levels for psychosis, 
(3) BLIPS: an experience of a recent brief  psychotic ep-
isode which remitted within a week without the use of 
antipsychotic medications. Psychometric features of the 
UHR state have been described elsewhere.24 Exclusion 
criteria were the prior experience of a psychotic episode 
of more than one week or symptoms relevant for inclu-
sion explained by a medical disorder or drug or alcohol 
dependence as assessed by the CAARMS, or an intelli-
gence quotient (IQ) below 60.
Assessment
Participants were invited for face-to-face follow-up 
meetings at 6 months (some sites only), 12 months, and 
24  months after baseline. In case face-to-face meetings 
were not possible, information regarding the transition to 
psychosis was followed up for 2 years using available clin-
ical records, and this follow-up was extended when addi-
tional clinical data was available.
The presence of a comorbid depressive or anxiety dis-
order was assessed with the SCID-I.25 This included the 
diagnosis of a past or current depressive episode, as well 
as a past and current diagnosis of any anxiety disorder 
including social phobia, specific phobia, panic disorder, 
obsessive-compulsive disorder (OCD), agoraphobia, 
general anxiety disorder (GAD), or anxiety disorder not 
otherwise specified (NOS).
Prodromal psychopathology was assessed with the 
CAARMS,23 a semi-structured interview with a total of 
27 items, clustered in seven subscales. In the current study, 
APS trajectories were identified based on the CAARMS 
positive symptom subscale (unusual thought content, 
non-bizarre ideas, perceptual abnormalities, disorganized 
speech). Symptom severity was operationalized by sum-
ming intensity*frequency scores of the corresponding 
items, as has previously been described.11,26 Transition to 
psychosis was defined as the development of psychotic 
disorder according to the CAARMS.23
Covariates
The following risk factors for the onset of psychosis were 
identified in recent meta-analyses and were included as a 
priori defined covariates in all analyses.27,28
Gender, ethnicity, current employment, baseline 
global functioning assessed using the disability score of 
the General Assessment of Functioning (GAF) scale,29 
negative, cognitive, motor, and general symptoms as-
sessed with the CAARMS (supplementary eMethod 2.1 
elaborates on the adapted general subscale) and child-
hood trauma measured with the Childhood Trauma 
Questionnaire (CTQ).30
Statistical Analysis
For the design of the study, we followed state-of-the-art 
guidelines (GRoLTS checklist) for reporting latent trajec-
tory studies.31 Latent class mixed model analysis (LCMM) 
was used to identify and visualize clusters of participants 
with similar distinct APS outcome trajectories over time 
within one sample (supplementary eMethod 2.2 elabor-
ates on possible distinct trajectories). Missing values on 
main outcome and covariates at baseline were replaced 
applying multiple imputation procedures to be able to 
include participants with at least one assessment. With 
maximum likelihood (ML) estimation LCMM then 
makes use of all available data, regardless of intermittent 
missing data and/or later dropout. Subject and time were 
used to infer latent class trajectories of APS. The actual 
individual time of measurement (days since baseline) was 
used to account for possible deviation around the planned 
assessment date. The maximum observational period was 
set to <1000 days to avoid including large outlying values 
(>2SD). We chose to use unconditional LCMM to first 
describe the “raw” latent trajectories in the UHR popu-
lation without imposing any conditions/predictors on the 
model. In a subsequent step, we explored the prognostic 
validity of past, baseline, and one-year comorbidity of 
anxiety and depression on these unconditional trajec-
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Starting with a one-class model, we fitted models with 
increasing numbers of classes until we reached the inflec-
tion point of the Akaike information criterion (AIC). The 
AIC can be used to identify the point at which the benefits 
of improved model fit are outweighed by the cost of the 
model in terms of its complexity and thus helps to pre-
vent overfitting of the data. In addition, we examined the 
somewhat stricter Bayesian information criterion (BIC), 
and the log-likelihood (LL). The latter is a measure of 
goodness of model fit regardless of model complexity. 
Finally, posterior probabilities of class membership for 
each patient were computed using the Bayes theorem.32 
According to the GRoLTS checklist the final model was 
selected based on both statistical (log-likelihood, AIC, 
BIC) and clinical (class size, distinctness of class-specific 
trajectories, likelihood of class membership based on 
posterior probabilities) considerations. For more detailed 
information on LCMM see supplementary eMethod 2.3.
According to the standard Three-Step Method,31 un-
conditional trajectories were identified as described above 
(step 1) and class membership was saved and merged with 
the original data (step 2). Multinomial logistic regression 
analyses were subsequently used to examine predictors 
of APS trajectory class membership as the response vari-
ables and past, baseline, or one-year comorbid diagnosis 
of anxiety/depression as candidate explanatory variables 
(step 3). A  priori selected covariates were entered in a 
first block to the model, followed by comorbidity in a 
second block.
To assess the effect of past, baseline, and one-year af-
fective comorbidity on the development of psychotic 
disorders within the two-year follow-up interval Cox 
proportional hazard regression analyses were conducted 
after assessing the proportional hazards assumption.
The overall cumulative risk of psychosis onset for in-
dividuals with presence versus absence of a comorbid 
affective disorder was plotted with the Kaplan–Meier 
cumulative event function and 95% confidence intervals 
(CI). We reported the numbers of those at-risk and trun-
cate the event function when less than 30 subjects were 
still at risk.33
LCMM was conducted using the lcmm R package.34 
Cox proportional hazard regression analyses were ana-
lyzed using survival R package35 and survminer R 
package33 to plot Kaplan–Meier functions with R version 




In total, 345 UHR subjects participated in the EU-GEI 
study. The sample of the current study consisted of 331 
individuals, as 14 participants had no valid SCID data 
and had to be excluded (see flow-chart figure 1 for more 
information including follow-up data). Median follow-up 
periods were 202 days (min = 41, max = 283) for 6 months 
assessment, 397  days (min  =  277, max  =  554) for one-
year, and 760 days (min = 533 and max = 992) for two-
years assessment.
At baseline, 110 (33.2%) participants had current co-
morbid depression and 123 (37.2%) current anxiety dis-
order. Retrospectively, 155 (46.8%) individuals reported 
a past major depressive episode, whereas 142 (42.9%) 
reported at least one past anxiety disorder. Regarding 
persistence across these two assessments, n = 50 (15.1%) 
individuals reported persistence in depression, whereas 
n = 104 (31.4%) fulfilled the criteria for an anxiety dis-
order both at baseline and in the past. At one-year fol-
low-up 24 (15.3%) and 43 (27.4%) participants fulfilled 
the criteria for depressive or anxiety disorder, respectively. 
Data regarding missingness at baseline, and comparisons 
between dropouts and completers at one-year are pre-
sented as supplementary eResults 3.1 & 3.2. Comparing 
completers and dropouts at one-year follow-up showed 
no significant differences on any of the sociodemographic 
or clinical variables at baseline, except for slightly lower 
years of education and a higher percentage of baseline 
depressive disorders in dropouts.
Sociodemographic characteristics and baseline clinical 
variables by trajectory are presented in table 1.
Trajectories of Attenuated Psychotic Symptom Severity
A 3-class model was selected for APS trajectories as the 
associated AIC was the lowest among the tested models. 
The BIC was similar to the 2-class solution and consid-
erably lower than the 4-class solution (table 2). For the 
3-class model, mean class probabilities were moderate to 
high (0.70–0.88), suggesting individuals had a 70%–88% 
probability to be correctly assigned to one of the three 
Fig. 1. Flowchart of included participants. Abbreviation: 
CAARMS: the Comprehensive Assessment of At-Risk Mental 
States; SCID: Structured Clinical Interview for DSM-IV-TR Axis 
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latent classes. After visual inspection of the identified tra-
jectories, the classes could be defined as: (1) persistently 
low symptom severity (n = 238), (2) increasing symptom 
severity (n  =  28), and (3) decreasing symptom severity 
n = 65), see figure 2. For observed individual courses of 
CAARMS positive scores by most likely trajectory mem-
bership see supplementary eFigures 2a-c.
Predictors of Latent Trajectory Class Membership
Multinomial logistic models were conducted to investigate 
whether past, baseline, or one-year comorbid diagnosis 
of depression or anxiety disorder were associated with a 
higher likelihood for the unfavorable, increasing trajec-
tory of APS, accounting for a priori selected covariates.
Adding past comorbidity to a priori defined covariates 
improved the model's fit (-2LL: 470.631–461.381) and 
increased Nagelkerke R2 from .128 to .160. Past anxiety 
disorder showed a trend-level association with a lower 
likelihood (odds ratio (OR) = .443, P = .077) of belonging 
to the increasing trajectory group compared to the persist-
ently low trajectory group. In contrast, a past diagnosis 
of depression was significantly associated with a higher 
Table 1. Baseline Information on Sociodemographic and Clinical Variables by Trajectory Class
Class 1 (Persistently Low) 
N = 238
Class 2 (Decreasing) 
N = 65




Age 22.39 (4.95) 22.53 (4.70) 23.38 (6.57) F = .471, P = .625
Gender (% male) 52.52 56.92 60.71 X = .941, P = .625
Ethnicity (% caucasian) 72.26 63.08 78.57 X = 2.95, P = .229
Years of education 14.28 (2.98) 14.44 (3.37) 13.76 (3.36) F = .354, P = .702
Cannabis use (% yes)a 27.31 26.15 28.57 X = .064, P = .969
Cannabis abuse (% yes) 11.22 16.31 22.21 X = 2.360, P = .307
Currently employed (yes %) 75.98 83.87 74.07 X = 1.915, P = .284
UHR intake group (%)    X = 36.595, P < .001
 APS 78.2 60.7 74.1  
 GRD 10.7 0 7.4  
 BLIPS 1.8 13.1 0  




29.9 32.7 22.7 X = .717, P = .699
 Anxiolytics 10.0 10.2 0 X = 2.426, P = .297
 Antipsychotics 8.5 12.2 13.6 X = 1.114, P = .573
CAARMS
 Positive 29.84 (13.35) 63.84 (14.44) 34.71 (12.88) F = 161.67, P < .001
 Negative 29.45 (18.41) 28.78 (18.29) 29.18 (16.30) F = 0.04, P = .965
 Cognitive 9.50 (5.92) 10.96 (6.07) 10.55 (6.72) F = 1.68, P = .186
 Emotional 12.31 (11.04) 13.33 (11.36) 12.39 (11.68) F = .210, P = .810
 Social 31.08 (19.72) 33.08 (18.31) 32.99 (21.87) F = .336, P = .715
 Motor 6.15 (7.90) 10.08 (12.72) 8.69 (11.32) F = 4.95, P = .008
 General 20.87 (15.52) 28.70 (18.81) 26.28 (17.66) F = 6.482, P = .002
Abbreviations: CAARMS: the Comprehensive Assessment of At-Risk Mental States, APS: attenuated psychotic symptoms, BLIPS: brief  
intermittent psychotic symptoms, GRD: Genetic Risk and Deterioration syndrome.
aAssessed with the Cannabis Experiences Questionnaire (CEQ).
bInformation available in a subsample of n = 272.











1 6 6261.687 6284.500 −3124.844   
2 9 6216.362 6250.581 −3099.18 .86–.92 303/28
3 12 6205.759 6251.384 −3090.879 .70–.88 28/238/65
4 15 6209.673 6266.705 −3090.000 .51–.82 18/34/249/30
5 18 6215.673 6284.111 −3089.836 .53–.87 27/239/30/35/0
Note: 3-class model fit parameters are highlighted in bold.
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likelihood to belong to the increasing group compared to 
the persistently low group (OR = 3.149, P = .011) or the 
decreasing group (OR = 3.137, P = .024) (table 3).
Adding baseline comorbidity to the model after ac-
counting for covariates, slightly improved model fit (-2LL: 
470.631–466.858) and increased Nagelkerke R2 from .128 
to .142 approximated explained variance. Baseline anx-
iety disorder was associated with a lower likelihood to 
show an increase in APS severity over time again on a 
trend-level (OR = .414, P = .075) compared to the per-
sistently low course. No significant associations were 
found for baseline depression (table 3).
Neither the presence of an anxiety nor of a depressive 
diagnosis at one-year follow-up predicted any of the three 
trajectories in the smaller subsample of n = 157 (persist-
ently low n = 115, increasing n = 18, decreasing n = 24) 
(see table  3). Although the model fit slightly improved 
(-2LL: 220.573–218.010) and Nagelkerke R2 increased 
from .154 to .172.
When including both baseline and lifetime 
comorbidities in one model (Nagelkerke R2 = .167), only 
past depression remained a significant predictor of the 
increasing trajectory group compared to the persist-
ently low group (P = .011, OR = 3.201 [95%CI = 1.308–
7.831]) and the decreasing group (P = .022, OR = 3.226 
[95%CI = 1.187–8.772]), respectively.
Comorbid Affective Disorders and Risk for Transition
Transition to psychosis data were available on 99% 
(n  =  328) of the current sample. Within the two-year 
period, 55 (16.7%) UHR individuals transitioned to 
Table 3. Results of Multinomial Regression Analysis of Past, Baseline (n = 331), and One-year (n = 157) Comorbid Anxiety and 
Depression in Predicting Attenuated Psychotic Symptom Trajectories
Past Comorbidity Baseline Comorbidity One-year Comorbidity
 Exp(B) 95% CI P Exp(B) 95% CI P Exp(B) 95% CI P
Increasing vs. persistently low trajectory
Ethnicity .694 .251–1.921 .482 .679 .245–1.881 .457 1.032 .286–3.734 .961
Gender .551 .230–1.322 .182 .644 .276–1.505 .310 .701 .229–2.145 .533
Currently employed 1.201 .485–2.976 .629 1.206 .485–2.996 .687 1.672 .517–5.403 .390
GAF 1.001 .961–1.042 .972 1.000 .960–1.042 .998 .998 .944-1.054 .933
Trauma 1.028 1.000–1.057 .047 1.024 .997–1.053 .087 1.017 .982–1.053 .345
Negative symptoms .988 .961–1.015 .375 .990 .962–1.018 .466 .971 .953–1.009 .128
Cognitive symptoms 1.029 .956–1.107 .453 1.024 .951–1.102 .527 1.004 .910–1.108 .932
Motor symptoms 1.034 .990–1.080 .134 1.029 .986–1.073 .189 1.023 .966–1.084 .433
General symptoms 1.012 .985–1.041 .390 1.015 .988–1.043 .281 1.037 1.000–1.076 .047
Anxiety .443 .179–1.094 .077 .414 .156–1.094 .075 1.187 .361–3.898 .778
Depression 3.149 1.298–7.642 .011 1.093 .429–2.783 .852 .508 .097–2.665 .423
Increasing vs. decreasing trajectory
Ethnicity .387 .128–1.176 .094 .383 .126–1.166 .091 .671 .145–3.113 .611
Gender .793 .297–2.121 .645 .944 .362–2.459 .906 1.926 .455–8.149 .373
Currently employed .849 .308–2.343 .752 .855 .309–2.366 .762 .751 .180–3.143 .695
GAF .983 .939–1.028 .450 .983 .939–1.028 .454 .969 .908–1.034 .347
Trauma 1.019 .989–1.051 .218 1.015 .984–1.046 .353 1.018 .974–1.064 .432
Negative symptoms 1.009 .977–1.041 .596 1.010 .978–1.043 .546 .975 .931–1.020 .271
Cognitive symptoms 1.002 .923–1.087 .967 .996 .918–1.081 .928 1.032 .916–1.164 .602
Motor symptoms .994 .949–1.040 .786 .989 .946–1.034 .629 1.009 .966–1.053 .383
General symptoms .980 .950–1.010 .188 .982 .953–1.013 .250 .980 .950–1.010 .688
Anxiety .511 .187–1.394 .190 .440 .151–1.282 .133 2.662 .500–14.169 .251
Depression 3.137 1.165–8.450 .024 1.266 .441–3.3640 .661 .489 .069–3457 .473
Note: Significant and trend-level associations are highlighted in bold.
Fig. 2. Model estimated class-specific mean predicted trajectories 
of attenuated psychotic symptoms with 95% confidence intervals. 
Trajectories were classified as “persistently low” (n = 238; 71.9%), 
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psychosis, this included 19 individuals from the increasing 
group, 22 from the persistently low, and 14 from the 
decreasing group. The average follow-up time was 
423.78 days (SD = 325.05). The last transition was ob-
served at 779 days when 29 individuals were still at-risk. 
The median time to transition was 219.0 days (25th–75th 
percentiles 121–398).
Cox proportional hazard regression analyses showed 
a 2-fold (HR  =  2.132; 95%CI: 1.178–3.828, P  =  .012) 
higher cumulative risk to develop a psychotic disorder in 
the group with a past depressive episode (n = 36 [23.4%]) 
compared to the group without past depression (n = 19 
[10.9%]), while controlling for the same a priori defined 
covariates. The corresponding Kaplan–Meier cumulative 
risk of psychosis curve is depicted in figure 3. No signif-
icant differences for transition risk were found with re-
gard to baseline or one-year depression or past, baseline, 
or one-year anxiety disorder (see table 4). For remaining 
Kapan–Meier curves see supplementary eFigures 3a-e.
Discussion
To our knowledge, this is the first study investigating re-
peatedly assessed diagnoses of comorbid anxiety or de-
pression as potential predictors of distinct trajectories 
of APS severity. We found that the severity of APS can 
be clustered across three trajectories: persistently low, 
increasing, and decreasing. Controlling for several known 
predictors (supplementary eDiscussion 4.1 elaborates 
on baseline CAARMS differences between trajectory 
groups) of risk to transition, we demonstrated that past 
depression had a negative impact on the course of APS 
in UHR. In contrast, past and baseline anxiety disorder 
showed a trend association for a persistently low course. 
No effects were found for affective disorders assessed at 
one-year follow-up.
Almost half  (46.8%) of the UHR participants in the 
current study reported a past depression, and 33.2% ful-
filled the criteria for a current depressive episode at base-
line. Similarly, 42.9% reported any past, and 37.2% any 
baseline anxiety disorder. The prevalence of baseline co-
morbid depression is slightly lower than meta-analytical 
estimations of 41%, whereas the prevalence of baseline 
comorbid anxiety exceeds previously reported mean esti-
mates of 15%.36 Contrasting findings might be explained 
by a more narrow focus on depressive episodes on the 
one hand and inclusion of a broader range of anxiety 
disorders (eg, including specific phobia, general anxiety 
disorder, and OCD) on the other hand. Indeed, studies 
addressing similar wider diagnostic spectra for anxiety 
disorders have confirmed comparably high (38.5%)37 or 
even higher (51%)38 prevalence rates in UHR individ-
uals. Remission of comorbid depressive disorders over 
the course of the study in more than half  of subjects and 
persistence in anxiety disorders in the majority of partici-
pants is in line with previous observations.39
According to our first aim to examine trajectories of 
APS, we identified a 3-class model with the vast ma-
jority (91.5%) of UHR individuals belonging to the per-
sistently low or decreasing trajectory group, whereas a 
small group (8.5%) showed an increase of APS severity 
over a 2-year period. Regarding the prognostic validity 
of repeatedly assessed affective comorbidities, a past di-
agnosis of depression was associated with 3-fold higher 
odds of increased APS severity over time compared to 
the persistently low (OR  =  3.149) and the decreasing 
group (OR  =  3.137), respectively. In contrast, a past 
(OR  =  .443) and baseline (OR  =  .414) comorbid diag-
nosis of anxiety, showed trend-level associations with a 
lower likelihood to belong to the increasing symptom 
severity trajectory group. However, the presence of con-
siderably large confidence intervals needs to be acknowl-
edged. Non-significant associations between comorbidity 
at one-year and APS trajectories were limited by a smaller 
Fig. 3. Cumulative event Kaplan–Meier function for risk of 
development of psychotic disorders with 95% Confidence 
Intervals in 328 ultra-high risk (UHR) individuals stratified for 
past depression.
Table 4. Hazard Ratio (HR) for Past, Baseline, and One-year 
Affective Comorbidities and Transition Risk Adjusted for 
Covariates
HR 95% CI P
Depression
Past 2.132 1.178–3.828 .012
Baseline 1.020 .533–1.952 .953
One-year 1.568 .519–4.736 .425
Anxiety
Past 1.203 .683–2.120 .522
Baseline .872 .485–1.569 .649
One-year .840 .296–2.384 .743
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sample size. Few previous studies have investigated trajec-
tories of APS or psychotic-like experiences with similar 
methodological approaches.40–42 Only one study reported 
on positive associations between an unfavorable course 
of self-reported psychotic-like experiences and elevated 
scores in depression and anxiety in a sample of adoles-
cents.42 No study investigated the prognostic value of 
comorbid DSM-IV affective disorders on identified tra-
jectories. Studies investigating remission from the UHR 
state also found no associations with the presence of a 
baseline comorbid diagnosis of depression.5
However, a lower likelihood for remission was found in 
UHR individuals with a lifetime (past or present) diag-
nosis compared to those with no history of depression.17 
Regarding associations with baseline comorbid anxiety 
disorders, two previous studies found associations with a 
lower number of APS remission at follow-up.5,38 The au-
thors argued that the co-occurrence of anxiety disorders 
and subclinical positive symptoms might constitute a 
specific subgroup of UHR individuals, where anxiety was 
specifically associated with more suspiciousness, but not 
with any other APS.38 These psychotic experiences might 
be closely linked to anxiety content, persist over time, but 
not ultimately progress to diagnosable psychosis.43,44 In 
support of this hypothesis, one study reported a lower 
likelihood for transition to psychosis in UHR individuals 
with current anxiety disorders in the European Prediction 
of Psychosis (EPOS) Study.43
With regard to our secondary aim, Cox regression ana-
lyses showed a more than 2-fold higher risk to develop 
a psychotic disorder for individuals reporting a past de-
pressive disorder (HR  =  2.132). However, no effect of 
baseline or one-year depression or past, baseline, or one-
year anxiety disorders was found. This is in line with pre-
vious meta-analytical findings reporting no association 
between current comorbid affective disorders and tran-
sition risk.36 To the best of our knowledge, no previous 
study investigated associations with past diagnoses.
Current findings suggest that particularly the experi-
ence of a past depressive episode might negatively influ-
ence the course of APS in UHR individuals. Affective 
dysregulation and mood disorders possibly proceeding 
APS onset during adolescents and time of major neu-
robiological development have been suggested to lead 
to and reinforce psychotic experiences.45 In this line, an 
affective pathway to psychosis has been suggested with 
affective dysregulation as the main connective compo-
nent between early traumatic or stressful experiences and 
psychosis onset.9,46,47 Furthermore, indirect effects of af-
fective symptoms via decline in psychosocial and global 
functioning on longitudinal outcome in UHR popu-
lations have been suggested.14,48 One study showed that 
especially functional deterioration starting well before 
the 12 months prior to baseline assessment was associ-
ated with an increased risk of psychosis.49 In contrast, 
psychotic symptoms co-occurring with anxiety disorders 
have not been associated with increased severity over time 
or the risk to convert to full-blown psychosis44 (supple-
mentary eDiscussion 4.2 elaborates on the co-occurrence 
of (subclinical) psychotic and affective symptoms).
Clinical and Research Implications
The current findings may have clinical implications for 
the detection, prognostic assessment, and intervention in 
UHR individuals. From detection and prognostic perspec-
tives, the assessment of early depressive episode, might 
be valuable in the prediction of an unfavorable course in 
a small subgroup of UHR individuals. Broadening the 
UHR state to enhance a transdiagnostic perspective50–53 
may have potential benefits in this regard. A suggestion 
has been to expand it to other subsyndromal dimensions 
such as subthreshold bipolar states, mild-moderate de-
pression, and borderline personality features.51 However, 
the prognostic validity of this approach awaits empirical 
validation. Another promising approach would be to in-
corporate prediction models based on individual patients 
data to enhance stratification or personalization of pre-
dictions within UHR samples.1,54
From an interventional perspective, currently, there is 
no meta-analytical evidence that preventive psycholog-
ical treatments targeting APS are superior to needs based 
interventions.55,56 However, wide confidence intervals of 
effects suggest that interventions may be effective for 
some UHR subgroups.
In this line, identified trajectories and potential dif-
ferential effects of comorbid depressive and anxiety dis-
orders suggest different needs for clinical interventions. 
It is important to acknowledge that the percentage of 
subjects with an increasing course or transition to psy-
chosis is relatively small. However, accurate detection of 
this small subgroup of patients and their prioritization 
into preventive healthcare pathways that focus on affec-
tive dysregulation may optimize the efficiency of preven-
tive approaches, saving on the vast majority which may 
not need such type of intervention. Another subgroup of 
UHR individuals might profit from a specific focus on 
reported anxiety disorders, which might help to reduce 
content-related subclinical psychotic symptoms.
Limitations
Results should be interpreted in light of several limita-
tions. First, predictors included in the current analyses 
left considerable variance unexplained. These results sug-
gest that critical factors that might more directly affect 
the course of APS over time were not included as poten-
tial determinants. For example, it was not possible to take 
the effect of pharmacological interventions into account 
as this information was only available in a subgroup of 
participants. Noteworthy, within this subgroup, no sig-
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use were found between the trajectories. Although a 
priori selected confounders were identified as risk fac-
tors for transition, other factors could also have been 
relevant in predicting APS trajectories. Third, the rela-
tively small group of participants in the increasing and 
decreasing trajectory group, in combination with consid-
erable dropout during the course of the study, limits the 
reliability of assessed associations between identified tra-
jectories and comorbid diagnosis at one-year follow-up. 
The question of whether a repeated assessment of affec-
tive comorbidities may provide valuable information in 
the prediction of clinical outcome in UHR individuals 
thus needs further investigation. Fourth, due to too small 
sample sizes, we were unable to differentiate the group of 
UHR individuals who were diagnosed with both anxiety 
and depression from those diagnosed with only one of 
the two. Hence, more research is needed to investigate the 
effect of a combination of comorbid diagnoses. This is a 
relevant limitation, as previous studies have shown higher 
functional impairment and CAARMS symptom severity 
in the group with combined anxiety and depression com-
pared to either alone.36 Fifth, the percentage of baseline 
comorbid diagnosis of depression was larger in partici-
pants lost to follow-up. This might have led to an under-
estimation of the association between baseline depressive 
disorders and the prospective course of APS. Sixth, past 
affective comorbidities were assessed retrospectively, 
which might limit the reliability of these data. If  possible, 
future studies should integrate information from clinical 
case records and/or family members. In addition, future 
prospective investigations in earlier stages of the at-risk 
mental stage (eg, prior to help-seeking) would shed more 
light on the impact and possible mechanisms of early af-
fective disturbances on clinical outcome.
Conclusion
A large group of UHR individuals fulfill the criteria for 
co-occurring depressive or anxiety disorders. Results of 
the current study suggest that particularly the experi-
ence of a past depressive episode might be a relevant risk 
factor for an unfavorable course of APS in UHR individ-
uals and increase the risk of transition to psychosis.
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Supplementary data are available at Schizophrenia 
Bulletin online.
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